Login to Your Account



In The Clinic NEWS

Seattle Genetics Inc. (Seagen) started its second-ever phase III study, pitting a CD33-targeted antibody-drug conjugate paired with widely used HMA vs. HMAs alone in older patients with newly diagnosed AML.

With a pivotal phase II/III trial to start "in the next several weeks," Oxigene Inc. CEO William Schwieterman said that the just-published results on CA4P paired with approved cancer therapy Avastin in recurrent ovarian cancer "are potentially huge for the field" of vascular-targeted therapy in solid tumors.

Preliminary data from a pivotal phase III test of experimental HIV drug ibalizumab helped 82.5 percent of patients receiving it meet the study's primary endpoint of a decrease of ≥ 0.5 log10 in viral load following a seven-day treatment period.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: